Chemical struction of clopidogrel bisulfate
Find information on thousands of medical conditions and prescription drugs.

Clopidogrel

Clopidogrel, which is often prescribed under the brand name Plavix® (clopidogrel bisulfate; produced by Bristol-Myers Squibb and Sanofi-Aventis), is a potent oral antiplatelet agent often used in the treatment of coronary artery disease, peripheral vascular disease, and cerebrovascular disease. more...

Home
Diseases
Medicines
A
B
C
Cabergoline
Caduet
Cafergot
Caffeine
Calan
Calciparine
Calcitonin
Calcitriol
Calcium folinate
Campath
Camptosar
Camptosar
Cancidas
Candesartan
Cannabinol
Capecitabine
Capoten
Captohexal
Captopril
Carbachol
Carbadox
Carbamazepine
Carbatrol
Carbenicillin
Carbidopa
Carbimazole
Carboplatin
Cardinorm
Cardiolite
Cardizem
Cardura
Carfentanil
Carisoprodol
Carnitine
Carvedilol
Casodex
Cataflam
Catapres
Cathine
Cathinone
Caverject
Ceclor
Cefacetrile
Cefaclor
Cefaclor
Cefadroxil
Cefazolin
Cefepime
Cefixime
Cefotan
Cefotaxime
Cefotetan
Cefpodoxime
Cefprozil
Ceftazidime
Ceftriaxone
Ceftriaxone
Cefuroxime
Cefuroxime
Cefzil
Celebrex
Celexa
Cellcept
Cephalexin
Cerebyx
Cerivastatin
Cerumenex
Cetirizine
Cetrimide
Chenodeoxycholic acid
Chloralose
Chlorambucil
Chloramphenicol
Chlordiazepoxide
Chlorhexidine
Chloropyramine
Chloroquine
Chloroxylenol
Chlorphenamine
Chlorpromazine
Chlorpropamide
Chlorprothixene
Chlortalidone
Chlortetracycline
Cholac
Cholybar
Choriogonadotropin alfa
Chorionic gonadotropin
Chymotrypsin
Cialis
Ciclopirox
Cicloral
Ciclosporin
Cidofovir
Ciglitazone
Cilastatin
Cilostazol
Cimehexal
Cimetidine
Cinchophen
Cinnarizine
Cipro
Ciprofloxacin
Cisapride
Cisplatin
Citalopram
Citicoline
Cladribine
Clamoxyquine
Clarinex
Clarithromycin
Claritin
Clavulanic acid
Clemastine
Clenbuterol
Climara
Clindamycin
Clioquinol
Clobazam
Clobetasol
Clofazimine
Clomhexal
Clomid
Clomifene
Clomipramine
Clonazepam
Clonidine
Clopidogrel
Clotrimazole
Cloxacillin
Clozapine
Clozaril
Cocarboxylase
Cogentin
Colistin
Colyte
Combivent
Commit
Compazine
Concerta
Copaxone
Cordarone
Coreg
Corgard
Corticotropin
Cortisone
Cotinine
Cotrim
Coumadin
Cozaar
Crestor
Crospovidone
Cuprimine
Cyanocobalamin
Cyclessa
Cyclizine
Cyclobenzaprine
Cyclopentolate
Cyclophosphamide
Cyclopropane
Cylert
Cyproterone
Cystagon
Cysteine
Cytarabine
Cytotec
Cytovene
Isotretinoin
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Pharmacology

The mechanism of action of clopidogrel is irreversible blockade of the adenosine diphosphate (ADP) receptor on platelet cell membranes. This receptor is named P2Y12 and is important in platelet aggregation, the cross-linking of platelets by fibrin. The blockade of this receptor inhibits platelet aggregation.

Two hours after a single dose of oral Plavix®, platelet inhibition can be demonstrated.

Pregnancy category

Clopidogrel is pregnancy category B. This means that in animal models, there is no risk of adverse effects in doses equivalent to doses that a pregnant female would ingest. The implication is that the medication is probably safe to administer during human pregnancy. It is currently unknown whether clopidogrel is excreted in human breast milk.

Adverse effects

Serious adverse effects that are associated with clopidogrel include:

  • Severe neutropenia (Incidence: 5/10,000)
  • Thrombotic thrombocytopenic purpura (TTP) (Incidence: 4/1,000,000 patients treated)
  • Hemorrhage - The incidence of hemorrhage may be increased by the co-administration of aspirin.
    • Gastrointestinal Hemorrhage (Incidence: 2.0%)
    • Cerebral Hemorrhage (Incidence: 0.1 to 0.4%)

Most consensus-based therapeutic guidelines recommend the use of clopidogrel, over aspirin, in patients requiring antiplatelet therapy but with a history of gastric ulceration due to the lower incidence of gastric ulceration associated with the use of clopidogrel vs aspirin. A recent study has shown that in patients with healed aspirin-induced ulcers, however, patients receiving aspirin plus the proton pump inhibitor esomeprazole had a lower incidence of recurrent ulcer bleeding than patients receiving clopidogrel. (Chan et al., 2005)

Read more at Wikipedia.org


[List your site here Free!]


Clopidogrel as antithrombotic therapy in atrial fibrillation
From CHEST, 7/1/05 by Henrique H. Veloso

To the Editor:

Clopidogrel is a new antiplatelet drug that has been largely used in several settings of coronary artery disease. Its role in the prevention of thromboembolic events in patients with atrial fibrillation was not definitely stated, but some preliminary randomized trials have been recently published. However, these initial experiences were not mentioned in the excellent article of Singer et al (1) regarding antithrombotic therapy in atrial fibrillation from the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Initially, Muller et al (2) evaluated the effect of the association of aspirin (300 mg/d) plus clopidogrel (75 mg/d) vs oral anticoagulation (international normalized ratio, 2 to 3) on coagulation in 20 patients with nonvalvular atrial fibrillation. Aspirin plus clopidogrel significantly inhibited platelet aggregation, fibrinogen receptor activation and release of P-selectin, and prolonged in vitro bleeding time. Coagulation parameters (platelet-dependent thrombin generation, antithromhin III, thrombin-antithrombin III complex, prothrombin fragment 1 + 2) were not significantly affected. Thus, the authors concluded that combined antiplatelet therapy is superior to aspirin monotherapy in inhibiting platelet function but does not seem to substantially modulate coagulation cascade in patients with nonvalvular atrial fibrillation.

In the same year, Kamath et ala randomized 70 patients with nonvalvular atrial fibrillation to either dose-adjusted warfarin (international normalized ratio, 2 to 3) or combination therapy with aspirin (75 mg/d) and clopidogrel (75 rag/d). Pretreatment levels of fibrin d-dimer, [beta]-thromboglobulin, and soluble P-selectin were raised in patients with atrial fibrillation, whereas plasma prothrombin fragment 1 + 2 levels and platelet aggregation were not different from control subjects. Dose-adjusted warfarin reduced plasma levels of fibrin d-dimer, prothrombin fragment 1 + 2 and [beta]-thromboglobulin levels, enhanced plasma levels of soluble P-selectin, and had no significant effect on platelet aggregation. Aspirin plus clopidogrel therapy made no difference to the plasma markers of thrombogenesis or platelet activation, but the platelet aggregation responses to adenosine diphosphate and epinephrine were decreased. Thus, the authors concluded that association of aspirin plus clopidogrel failed to reduce plasma indexes of thrombogenesis and platelet activation in atrial fibrillation, although some aspects of ex vivo platelet aggregation were altered. They considered that anticoagulation with warfarin may be superior to combination of aspirin plus clopidogrel as thromboprophylaxis in atrial fibrillation.

Finally, Lorenzoni et al (4) evaluated the short-term safety and efficacy of aspirin plus clopidogrel as antithrombotic therapy in nonvalvular atrial fibrillation. Thirty patients with non-high-risk permanent or persistent atrial fibrillation awaiting cardioversion underwent transesophageal echocardiography to exclude left-heart thrombi and were randomized to receive warfarin (international normalized ratio, 2 to 3) or aspirin (100 mg/d) plus clopidogrel (75 mg/d). Bleeding time, not affected by warfarin, was prolonged by aspirin and further by adding clopidogrel. Thromboxmae [B.sub.2], not affected by warfarin, was reduced by aspirin but not further by clopidogrel. No thrombi or dense spontaneous echocontrast were found at the 3-week transesophageal echocardiography. Patients underwent electrical cardioversion to achieve sinus rhythm, and no thromboembolic or hemorrhagic events occurred in both study arms throughout the 3-week treatment and a further 3-month follow-up. Thus, the authors concluded that the combination of aspirin plus clopidogrel and warfarin were equally safe and effective in preventing thromboembolism in this small group of patients with non-high-risk atrial fibrillation.

These preliminary studies suggest that the association of clopidogrel to aspirin is superior to aspirin alone in the prevention of thromboembolic events in patients with atrial fibrillation. Compared with dose-adjusted oral anticoagulation, their data did not allow definite conclusions. Further randomized trials should be performed to define the role of the combination of clopidogrel plus aspirin in comparison with dose-adjusted warfarin in patients with atrial fibrillation.

Henrique H. Veloso, MD

Hospital da Venerdvel Ordem Terceira da PenitOncia

Rio de Janeiro

Angelo A. V. de Paola, MD

Federal University of Sao Paulo

Sao Paulo Brazil

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal. org/misc/reprints.shtml).

Correspondence to: Henrique H. Veloso, MD, Rua Lopes Quintas 244/106 bloco 1, Jardim Botanico, Rio de Janeiro-RJ, Brazil 22460-010; e-mail: hhorta@cardiol.br

REFERENCES

(1) Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:429S-456S

(2) Muller I, Massberg S, Zierhut W, et al. Effects of aspirin and clopidogrel versus oral anticoagulation on platelet function and on-coagulation in patients with nonvalvular atrial fibrillation (CLAFIB). Pathophysiol Haemost Thromb 2002; 32:16-24

(3) Kmnath S, Blann AD, Chin BS, et al. A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. J Am Coll Cardiol 2002; 40:484-490

(4) Lorenzoni R, Lazzerini G, Cocci F, et al. Short-term prevention of thromboembolie complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study. Am Heart J 2004; 148:e6

To the Editor:

We appreciate the thoughtful summary by Drs. Veloso and de Paola of early-stage studies on the antiplatelet and anticoagulant effects of combination therapy with aspirin and elopidogrel in patients with atrial fibrillation. Large randomized trials with clinical end points would be needed before we could formulate recommendations on the use of therapy with clopidogrel plus aspirin in patients with atrial fibrillation. We look forward to the results of the ACTWE (1) set of trials, and we anticipate including these results in the atrial fibrillation chapter in the next American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy.

Daniel E. Singer, MD

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal. org/misc/reprints.shtinl).

Correspondence to: Daniel Singer, MD, Massachusetts General Hospital-Medicine, Clinical Epidemiology Unit 550-9, Massachusetts General Hospital, Boston, MA 02114; e-mail: desinger@bies.bwh.harvard.edu.

REFERENCES

(1) Hohnloser SH, Connolly SJ. Combined antiplatelet therapyin atrial fibrillation: review of the literature and future research avenues. J Cardiovasc Electrophysiol 2003;14(suppl):S60-S63

COPYRIGHT 2005 American College of Chest Physicians
COPYRIGHT 2005 Gale Group

Return to Clopidogrel
Home Contact Resources Exchange Links ebay